Abstract:Background Remarkable advances for clinical diagnosis and treatment in cancers including lung cancer involve cell-free circulating tumor DNA (ctDNA) detection through next generation sequencing. However, before the sensitivity and specificity of ctDNA detection can be widely recognized, the consistency of mutations in tumor tissue and ctDNA should be evaluated. The urgency of this consistency is extremely obvious in lung cancer to which great attention has been paid to in liquid biopsy field. Methods We have developed an approach named systematic error correction sequencing (Sec-Seq) to improve the evaluation of sequence alterations in circulating cell-free DNA. Averagely 10 ml preoperative blood samples were collected from 30 patients containing pulmonary space occupying pathological changes by traditional clinic diagnosis. cfDNA from plasma, genomic DNA from white blood cells, and genomic DNA from solid tumor of above patients were extracted and constructed as libraries for each sample before subjected to sequencing by a panel contains 50 cancer-associated genes encompassing 29 kb by custom probe hybridization capture with average depth >40000, 7000, or 6300 folds respectively. Results Detection limit for mutant allele frequency in our study was 0.1%. The sequencing results were analyzed by bioinformatic expertise based on our previous studies on the baseline mutation profiling of circulating cell-free DNA and the clinicopathological data of these patients. Among all the lung cancer patients, 78% patients were predicted as positive by ctDNA sequencing when the shreshold was defined as at least one of the hotspot mutations detected in the blood (ctDNA) was also detected in tumor tissue. Pneumonia and pulmonary tuberculosis were detected as negative according to the above standard. When evaluating all hotspots in driver genes in the panel, 24% mutations detected in tumor tissue (tDNA) were also detected in patients blood (ctDNA). When evaluating all genetic variations in the panel, including all the driver genes and passenger genes, 28% detected in tumor tissue (tDNA) were also detected in patients blood (ctDNA). Positive detection rates of plasma ctDNA in stage I lung cancer patients is 85%, compared with 17% of tumor biomarkers. Conclusion We demonstrated the importance of sequencing both circulating cell-free DNA and genomic DNA in tumor tissue for ctDNA detection in lung cancer currently. We also determined and confirmed the consistency of ctDNA and tumor tissue through NGS according to the criteria explored in our studies. Our strategy can initially distinguish the lung cancer from benign lesions of lung. Our work shows that the consistency will be benefited from the optimization in sensitivity and specificity in ctDNA detection.

A comparative study on ctDNA and tumor DNA mutations in lung cancer and benign cases with a high number of CTCs and CTECs

"Liquid biopsy"-ctDNA detection with great potential and challenges.

The feasibility of using mutation detection in ctDNA to assess tumor dynamics

Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy

Comparison of the Somatic Mutations Between Circulating Tumor DNA and Tissue DNA in Chinese Patients with Non-Small Cell Lung Cancer.

The diagnostic value of circulating tumor cells and ctDNA for gene mutations in lung cancer.

The Early Diagnosis in Lung Cancer by the Detection of Circulating Tumor DNA

Clinical application of liquid biopsy based on circulating tumor DNA in non-small cell lung cancer

The functional and clinical roles of liquid biopsy in patient-derived models

Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA)

Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis

Comparative study on the mutation spectrum of tissue DNA and blood ctDNA in patients with non-small cell lung cancer

Clinical application of ctDNA in early diagnosis, treatment and prognosis of patients with non-small cell lung cancer

Circulating tumor cells and DNA as liquid biopsies

Comparative Analysis of the Representative Value of Somatic Mutation Profiles Derived from Ctdna and Other Updated Lung Tumor Biopsy Alternative in Non-Resectable Non-Small Cell Lung Cancer Patients.

Genomic Landscape and Tumor Mutational Burden Determination of Circulating Tumor DNA in Over 5,000 Chinese Patients with Lung Cancer

Advances in circulating tumor cells for early detection, prognosis and metastasis reduction in lung cancer

Comparison of Plasma to Tissue DNA Mutations in Surgical Patients with Non–small Cell Lung Cancer

Circulating Tumor DNA—A Novel Biomarker of Tumor Progression and Its Favorable Detection Techniques

Concordance of genomic mutations between tissue and ctDNA in non-small cell lung cancer: impact of time interval stratified by stage, smoking history and treatment

Liquid biopsy: Comprehensive overview of circulating tumor DNA (Review)